智通财经APP讯，欧康维视生物-B(01477)发布公告，董事会认为有必要实施激励措施以支持本集团的战略增长目标，并维持人才招聘及留任方面的竞争优势。为认可承授人致力于实现本集团研究及开发(研发)及商业里程碑所作的长期付出及宝贵贡献，董事会于2026年5月12日议决，根据 2021年购股权计划向498名承授人(包括本公司执行董事胡兆鹏博士(胡博士)及一名高级管理层成员)授出793.21万份涉及793.21万股股份的购股权，及根据2021年股份奖励计划向498名承授人(包括胡博士及一名高级管理层成员)授出 793.21万份涉及793.21万股股份的奖励，分别相当于截至授出日期本公司已发行及发行在外股份总数(不包括库存股份)约0.97%及0.97%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.